Scarica l'app Stockscreener
26.21
0.04%
-0.010
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$26.22
Aprire:
$26.69
Volume 24 ore:
5.46M
Relative Volume:
3.32
Capitalizzazione di mercato:
$3.28B
Reddito:
$415.62M
Utile/perdita netta:
$-2.38M
Rapporto P/E:
-922.89
EPS:
-0.0284
Flusso di cassa netto:
$16.92M
1 W Prestazione:
+6.59%
1M Prestazione:
+30.85%
6M Prestazione:
-5.65%
1 anno Prestazione:
+91.73%
Intervallo 1D:
$25.43
$27.00
Intervallo di 1 settimana:
$24.04
$27.00
Portata 52W:
$13.06
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.21 | 3.28B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Discipline and Rules-Based Execution in ARQT Response - Stock Traders Daily
Arcutis director Sue-Jean Lin sells $120,586 in company shares By Investing.com - Investing.com Australia
Insider Sell Alert: Sue-jean Lin Sells Shares of Arcutis Biother - GuruFocus
Arcutis Biotherapeutics Inc (ARQT) Institutional Confidence - TradingKey
Arcutis (ARQT) director Sue-Jean Lin executes planned share sale - Stock Titan
Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan - Stock Titan
Arcutis Biotherapeutics Inc (ARQT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Howard Welgus sells 21,240 ARQT shares (NASDAQ: ARQT) - Stock Titan
[144] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) Slips Slightly as Stock Holds Above Key SupportZero Gamma Level - newsline.com
Arcutis (ARQT) director amends filing to correct indirect share count - Stock Titan
Arcutis Biotherapeutics touts ZORYVE growth, FDA catalysts and cash-flow positive status - MSN
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) reports Q1 loss, beats revenue estimates - MSN
GW&K Investment Management LLC Sells 163,461 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status - sharewise.com
Arcutis (ARQT) director receives RSU grant and 16,667-share stock option - Stock Titan
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Arcutis Stockholders Approve Proposals at 2026 Meeting - TipRanks
Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay - Stock Titan
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors - GlobeNewswire Inc.
Geode Capital Management LLC Has $79.97 Million Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Arcutis hires receive 44,000 restricted stock units - Stock Titan
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 sees revenue beat, EPS miss - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - StreetInsider
New Expert Consensus Provides Age-Specific Guidance for - GlobeNewswire
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Hillsdale Investment Management Inc. Invests $5.21 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
ARQT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
(ARQT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37 - Moomoo
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Globe and Mail
Insiders At Arcutis Biotherapeutics Sold US$4.4m In Stock, Alluding To Potential Weakness - Moomoo
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):